Meiji Dairies Corporation

Renesas Electronics Corporation

Hiroto Suzuki

Masashi Yamada

Bang Luu

Yukie Suma

Djalil Coowar

Masayuki Uchida

Yoshinori Asakawa

Masao Miyagawa

Takeshi Watanabe

Motoaki Saito

Sachiko Okabe

Natsuko Murata

Ellane Mohier

Masao Ito

Osamu Matsumoto

Masaki Fujiwara

Takashi Matsumoto

Munekazu Iinuma

Tetsuo Matsui

Yukio Ohshiba

Tetsuro Matsuno

Toshiyuki Tanaka

Makoto Ubukata

Nobuyasu Matsuura

Patrick Neuberg

Delphine Trancard

Dominique Bagnard

Mazen Hanbali

A provided impedance measuring semiconductor circuit can suppress the influence of sensors on the measurements of other sensors in the measurements of the sensors. According to an embodiment, an impedance measuring semiconductor circuit includes a first resistance element, an operational amplifier having a positive input terminal and an output terminal, the positive input terminal receiving a predetermined set voltage, the output terminal being coupled to one end of the first resistance element, a first output-side switch that electrically couples or decouples a first sensor and the other end of the first resistance element, a second output-side switch that electrically couples or decouples a second sensor and the other end of the first resistance element, a first input-side switch that electrically couples or decouples the first sensor and a negative input terminal, and a second input-side switch that electrically couples or decouples the second sensor and the negative input terminal.

Impedance measuring semiconductor circuit

A processing speed can be improved while the accuracy of AD conversion is enhanced. An AD converter includes: a higher-order DAC that samples an analog input signal and performs DA conversion corresponding to higher-order bits of a digital output signal; an extension DAC that performs DA conversion to positive and negative polarities on an extension bit for expanding bits of the higher-order DAC; a lower-order DAC that performs DA conversion corresponding to lower-order bits of the digital output signal; a comparator that compares a comparison reference voltage with output voltages of the higher-order DAC, the extension DAC, and the lower-order DAC; and a successive approximation logic that controls successive approximation performed by the higher-order DAC, the extension DAC, and the lower-order DAC based on a comparison result of the comparator and generates the digital output signal.

AD converter, AD convert apparatus, and AD convert method

A successive approximation register A/D converter that obtains an output of N bits interrupts operation at a timing when the operation of the successive approximation register A/D converter is affected on the basis of circuit timing in an integrated circuit. The A/D converter performs a comparison between a sampling signal and a comparison reference voltage by a sampling period in which an analog signal is sampled, a comparison period of N states in which the sampled signal is sequentially compared with a comparison voltage for each bit, and a reserve period of M states following the comparison period. When an operation is temporarily interrupted, the A/D converter performs a comparison operation of a bit, whereas the comparison is not performed in the reserve period.

Integrated circuit

Provided is an indole long-chain alcohol, or a hydrate or an isomer thereof, represented by the following formula (I): 

Indole derivatives substituted with long-chain alcohols and medicaments containing them

The present invention provides compounds that are useful for preventing or treating brain dysfunctions, motor dysfunctions, or urinary dysfunctions caused by the degeneration and/or loss of the central nervous system or peripheral nervous system cells.

Hydroquinone long-chain derivatives and/or phenoxy long-chain derivatives, and pharmaceuticals comprising the same

The present invention relates to an agent for suppressing STAT3 phosphorylation and for suppressing Notch1 expression comprising as an active ingredient a compound represented by the following formula (1): 

STAT3 phosphorylation inhibitor and notch1 expression inhibitor

A preventive and/or therapeutic agent for diabetes complications, which comprises as an effective ingredient a cyclohexenone long-chain alcoholic derivative represented by the following formula (1): wherein, R, Rand Reach independently represents a hydrogen atom or a methyl group and X represents a linear or branched Calkylene or alkenylene group. The cyclohexenone long-chain alcoholic derivative of the present invention significantly suppresses a reduction in a peripheral nerve conduction rate and alleviates the hypofunction of the bladder so that it is useful as a preventive and/or therapeutic agent for diabetes complications, particularly, for diabetic neuropathy. 

Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications

Provided is an indole long-chain alcohol, or a hydrate or an isomer thereof, represented by the following formula (I): wherein R, R, Rand Reach independently represent a hydrogen atom, a methyl group, an acetyl group, or a hydroxyl group, and n represents a number fromtoand a medicinal composition comprising the same. The indole long-chain alcohol (I) exhibits an excellent nerve growth promoting effect, as well as potent antioxidative and anti-tumor effects, and is therefore useful as a prophylactic and/or therapeutic agent for cerebral diseases including dementia diseases, and malignant tumors including brain tumors.

The objective of the present invention is to identify compounds having an inhibitory effect on adipocyte differentiation, and to provide pharmaceutical compositions and food compositions for prevention, improvement, or treatment of obesity or obesity related diseases. By enthusiastically studying natural products that inhibit the differentiation induction of adipocyte precursors into adipocytes, sesquiterpenoid derivatives, which are extracts from a Compositae plant, Calea, growing in Central and South America, were demonstrated to have an excellent inhibitory effect on adipocyte differentiation induction. Calea extract or the sesquiterpenoid derivatives are expected to be used in pharmaceutical compositions and food compositions for prevention, improvement, or treatment of obesity related diseases.

Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect

An indole derivative represented by the following general formula (1): 

Indole derivatives and drugs containing the same

A process for producing cyclohexenone long-chain alcohol represented by the following formula (1): (wherein A represents a C10-C18 alkylene or alkenylene group, and each of R, R, and Rindividually represents hydrogen or methyl), comprising reacting a 3-alkoxy-2-cyclohexen-1-one derivative represented by the following formula (2): (wherein R, R, and Rhave the same meanings as above, and Rrepresents a C1-C5 alkyl group) with a Grignard's reagent prepared by protecting the hydroxyl groups of C10-C18 &#x3c9;-halogenoalcohol through silylation, and hydrolyzing the resultant reaction product. The process of the present invention for producing cyclohexenone long-chain alcohol requires a reduced number of reaction steps, can be performed with ease and with reduced production cost, and thus finds utility in the industry 

Process for producing cyclohexenone long-chain alcohols

The present invention provides a TNF-&#x3b1; production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-&#x3b1; production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-&#x3b1;, the agent containing a kavalactone as an active ingredient.

TNF-&#x3b1; production inhibitor comprising kavalactone as an active ingredient

A preventive and/or therapeutic agent for dysuria, which comprises as an effective ingredient a cyclohexenone long-chain alcoholic derivative represented by the following formula (1): [wherein, R, Rand Reach independently represents a hydrogen atom or a methyl group and X represents a linear or branched Calkylene or alkenylene group]. This compound alleviates dysuria due to hypofunction of the urinary bladder so that they are useful as a preventive and/or therapeutic agent for dysuria

Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria

The present invention provides a TNF-&agr; production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-&agr; production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-&agr;, the agent containing a kavalactone as an active ingredient.

Growing community of inventors

Tokyo, Japan

Hiroto Suzuki